| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3433102 | American Journal of Obstetrics and Gynecology | 2013 | 13 Pages |
Abstract
Despite studying a very large proportion of US deliveries, we did not find a significant increase in the risk of ACS or AMI in women who received methylergonovine compared with those who did not; estimates were increased only modestly or not at all. The upper limit of the 95% CI of our analysis suggests that treatment with methylergonovine would result in no more than 5 additional cases of ACS and 3 additional cases of AMI per 100,000 exposed patients.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Brian T. MD, MSc, Krista F. MS, PhD, Sonia MD, DrPH, Jun MS, Jeffrey L. MD, Jerry MD,